Biogen’s Good News Could Be Great News For Other Biotechs Focused On Neurodegenerative Diseases

The FDA’s approval of Biogen’s Alzheimer’s drug “has set a precedent, showing a much easier path to approval for investigative drug treatments focused on neurodegenerative diseases like Alzheimer’s and Parkinson’s where there is a significant unmet need,” declares the author of today’s article – and this lower bar for approval could help set the stage for a forceful biotech rally. For more – including some attractive neurodegenerative treatment companies that could be acquisition targets – CLICK HERE.